Cell therapy for prenatal repair of myelomeningocele: A systematic review.


Journal

Current research in translational medicine
ISSN: 2452-3186
Titre abrégé: Curr Res Transl Med
Pays: France
ID NLM: 101681234

Informations de publication

Date de publication:
11 2020
Historique:
received: 13 01 2020
revised: 13 04 2020
accepted: 23 04 2020
pubmed: 7 7 2020
medline: 7 10 2021
entrez: 7 7 2020
Statut: ppublish

Résumé

Myelomeningocele (MMC) is a spinal cord congenital defect that leads to paraplegia, bladder incontinence and bowel dysfunction. A randomized human trial demonstrated that in utero surgical repair of the MMC defect improves lower limb motor function. However, functional recovery remains incomplete. Stem cell therapy has recently generated great interest in the field of prenatal repair of MMC. In this systematic review we attempt to provide an overview of the current application of stem cells in different animal models of MMC. Publications were retrieved from PubMed and Cochrane Library databases. This process yielded twenty-two studies for inclusion in this review, experimenting five different types of stem cells: human embryonic stem cells, neural stem cells, induced pluripotent stem cells, human amniotic fluid stem cells, and mesenchymal stem cells (MSCs). Rodents and ovine were the two major species used for animal model studies. The source, the aims, and the main results were analyzed. Stem cell therapy appears to be a promising candidate for prenatal repair of MMC, especially MSCs. Further explorations in ovine and rodent models, reporting clinical and functional results, are necessary before an application in humans.

Identifiants

pubmed: 32624428
pii: S2452-3186(20)30032-5
doi: 10.1016/j.retram.2020.04.004
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

183-189

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

A Dugas (A)

Cell Therapy Unit, APHP, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, F75010, Paris, France; Université De Paris, Clinical Investigation Center in Biotherapies and UMR 976, Inserm, 1 Avenue Claude Vellefaux 75010 Paris, France.

J Larghero (J)

Cell Therapy Unit, APHP, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, F75010, Paris, France; Université De Paris, Clinical Investigation Center in Biotherapies and UMR 976, Inserm, 1 Avenue Claude Vellefaux 75010 Paris, France.

M Zérah (M)

Pediatric Neurosurgery Department, AP-HP, Necker-Enfants Malades Hospital, 149 Rue De Sèvres, F75015 Paris, France; Paris Descartes University, Paris France.

J M Jouannic (JM)

Fetal Medicine Department, APHP, Armand Trousseau Hospital, 26 Avenue Du Dr Arnold Netter, F75012 Paris, France; Sorbonne University, F75006 Paris, France.

L Guilbaud (L)

Cell Therapy Unit, APHP, Saint-Louis Hospital, 1 Avenue Claude Vellefaux, F75010, Paris, France; Université De Paris, Clinical Investigation Center in Biotherapies and UMR 976, Inserm, 1 Avenue Claude Vellefaux 75010 Paris, France; Fetal Medicine Department, APHP, Armand Trousseau Hospital, 26 Avenue Du Dr Arnold Netter, F75012 Paris, France. Electronic address: lucie.guilbaud@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH